Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 12/2015

01-12-2015 | Letter to the Editor

Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Authors: Klaus Müller, MD, MBA, Gunther Klautke, MD

Published in: Strahlentherapie und Onkologie | Issue 12/2015

Login to get access

Excerpt

In the article “Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck” Dornoff et al. suggested a new prognostic score for the survival of relapsed head and neck cancer patients after salvage treatment consisting of re-irradiation with concurrent immuno- or chemotherapy. Ranging from 0 to 4 points, the score classified patients into five groups with excellent (4 points), good (3 points), moderate (2 points), poor (1 point), and very poor (0 points) outcome. The authors finally stated that their tool would be useful to identify suitable patients for re-irradiation [1]. …
Literature
1.
Dornoff N, Weiss C, Rodel F, Wagenblast J, Ghanaati S, Nateghian A, Rodel C, Balermpas P (2015) Erratum to: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol. doi:10.1007/s00066-015-0882-7
2.
Müller K, Henke G, Compter I, von Bueren AO, Friedrich C, Janssens G, Kramm CM, Hundsberger T, Paulsen F, Kortmann RD, Zwiener I, Baumert BG (2014) External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation. Pract Radiat Oncol. doi:10.1016/j.prro.2014.10.001
3.
Royston P, Altman DG (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 13:33. doi:10.1186/1471-2288-13-33PubMedCentralCrossRefPubMed
Metadata
Title
Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck
Authors
Klaus Müller, MD, MBA
Gunther Klautke, MD
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 12/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0908-1

Other articles of this Issue 12/2015

Strahlentherapie und Onkologie 12/2015 Go to the issue

Letter to the Editor

Reply to: Comment on Dornoff et al.: re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Original Article

Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors

Literatur kommentiert

Hodgkin-Lymphom in Kindheit oder Jugend: Keine niedrigere Mutterschaftsrate nach Bestrahlungen außerhalb des Beckens

Original Article

VMAT to arclet plan conversion in a treatment planning system

Original Article

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas

Original Article

Stereotactic LINAC radiosurgery for the treatment of typical intracranial meningiomas